Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors

Cancer Genetics

Volumn 204, Issue 7, 2011, Pages 392-397

  Paquette, Ronald L ^a   Nicoll, John ^a   Chalukya, Meenal ^a   Elashoff, David ^b   Shah, Neil P ^c   Sawyers, Charles ^d   Spiteri, Elizabeth ^e   Nanjangud, Gouri ^a   Rao, P Nagesh ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UCSF Department of Medicine   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

BCR ABL1; Chronic myeloid leukemia; EVI1; Mutation; Myeloid blast crisis; Tyrosine kinase inhibitor

Indexed keywords

ABELSON KINASE; ANAGRELIDE; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; DASATINIB; DAUNORUBICIN; DOUBLE STRANDED DNA; ECOTROPIC VIRUS INTEGRATION SITE 1 PROTEIN; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; IMATINIB; INTERFERON; MITHRAMYCIN; MITOXANTRONE; NILOTINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ABL BCR FUSION PROTEIN, HUMAN; ABL-BCR FUSION PROTEIN, HUMAN; DNA BINDING PROTEIN; MECOM PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE COURSE; DNA REPAIR; ENZYME INHIBITION; EVI1 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; MALE; ONCOGENE; PRIORITY JOURNAL; UNIVARIATE ANALYSIS; WESTERN BLOTTING; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR EVOLUTION; MUTATION; PATHOLOGY; PROTO ONCOGENE;

ADULT; AGED; BLAST CRISIS; BLOTTING, WESTERN; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; FEMALE; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENES; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 80054777860     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2011.06.002     Document Type: Article

References (18)

1. Sawyers C.L., Hochhaus A., Feldman E., et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
2. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109:3207-3213.
3. Nucifora G. The EVI1 gene in myeloid leukemia. Leukemia 1997, 11:2022-2031.
4. Laricchia-Robbio L., Premanand K., Rinaldi C.R., et al. EVI1 impairs myelopoiesis by deregulation of PU.1 function. Cancer Res 2009, 69:1633-1642.
5. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
6. Lugthart S., Figueroa M.E., Bindels E., et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia. Blood 2011, 117:234-241.
7. Shah N.P., Nicoll J.M., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125.
8. Bobadilla D., Enriquez E.L., Alvarez G., et al. An interphase fluorescence in situ hybridization assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. Br J Haematol 2007, 136:806-813.
9. Przepiorka D., Thomas E.D. Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia. Bone Marrow Transplant 1988, 3:113-119.
10. Kharbanda S., Yuan Z.M., Weichselbaum R., et al. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998, 17:3309-3318.
11. Chen G., Yuan S., Liu W., et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex required ATM and c-Abl. J Biol Chem 1999, 274:12748-12752.
12. Shimizu H., Popova M., Fleury F., et al. c-ABL tyrosine kinase stabilizes RAD51 chromatin association. Biochem Biophys Res Comm 2009, 382:286-291.
13. Jones D., Luthra R., Cortes J., et al. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 2008, 112:5190-5192.
14. Cuenco G.M., Nicifora G., Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc Natl Acad Sci USA 2000, 97:1760-1765.
15. Cuenco G.M., Ren R. Cooperation of BCR-ABL and AML/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 2001, 20:8236-8248.
16. Weiser R. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 2007, 396:346-357.
17. Alzuherri H., McGilvray R., Kilbey A., et al. Conservation and expression of a novel alternatively spliced Evi1 exon. Gene 2006, 384:154-162.
18. Cuenco G.M., Ren R. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice. Oncogene 2004, 23:569-579.